VIVXF (Avivagen) Notes Receivable: $0.00 Mil (As of Jul. 2023)


What is Avivagen Notes Receivable?

Avivagen VIVXF -99.00% Notes Receivable is $0.00 Mil as of Jul. 2023.

Avivagen's Notes Receivable for the quarter that ended in Jul. 2023 was $0.00 Mil.

Avivagen Notes Receivable Historical Data

* Premium members only.

The historical data trend for Avivagen's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avivagen Notes Receivable Chart

Avivagen Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avivagen Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Avivagen Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Avivagen (VIVXF) has a Notes Receivable of $0.00 Mil as of Jul. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Avivagen and its competitors.
Is Avivagen's Notes Receivable too high?
Avivagen's current Notes Receivable is $0.00 Mil.
How does Avivagen's Notes Receivable compare to DMKPQ and MJNE?
Avivagen's Notes Receivable of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Avivagen and its competitors. Avivagen's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avivagen stock overvalued right now?
Avivagen (VIVXF) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Avivagen (VIVXF), the current Notes Receivable is $0.00 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avivagen Business Description

Address 100 Sussex Drive, Ottawa, ON, CAN, K1A 0R6
Avivagen Inc OxC-beta technology is derived from Avivagen discoveries about Beta-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxCbeta Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. Avivagen's OxC-beta Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters.